Orion Infusions (DHA:ORIONINFU) Accounts Payable: BDT50.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
80 GF Score
Price BDT288.90
GF Value BDT315.62
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Accounts Payable?

Orion Infusions DHA:ORIONINFU -0.48% 80 Accounts Payable is BDT50.5 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 80/100 and a GF Value™ of BDT315.62 (Fairly Valued). The stock has 3 warning signs investors should review.

Orion Infusions's Accounts Payable for the quarter that ended in Mar. 2026 was BDT50.5 Mil.

Orion Infusions's quarterly Accounts Payable declined from Sep. 2025 (BDT49.4 Mil) to Dec. 2025 (BDT46.5 Mil) but then increased from Dec. 2025 (BDT46.5 Mil) to Mar. 2026 (BDT50.5 Mil).

Orion Infusions's annual Accounts Payable increased from Jun. 2023 (BDT45.8 Mil) to Jun. 2024 (BDT53.2 Mil) and increased from Jun. 2024 (BDT53.2 Mil) to Jun. 2025 (BDT55.5 Mil).

Orion Infusions Accounts Payable Related Terms

Orion Infusions Accounts Payable Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Accounts Payable Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.34 40.66 45.84 53.21 55.55

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.23 55.55 49.41 46.54 50.46
DHA:ORIONINFU
80GF Score
Orion Infusions Ltd DHA:ORIONINFU
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of BDT50.5 Mil mean?
Orion Infusions (DHA:ORIONINFU) has a Accounts Payable of BDT50.5 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' Accounts Payable too high?
Orion Infusions' current Accounts Payable is BDT50.5 Mil. Overall, Orion Infusions has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Accounts Payable compare to ZTS and UTHR?
Orion Infusions' Accounts Payable of BDT50.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Orion Infusions and its competitors. Orion Infusions's current Accounts Payable is BDT50.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT315.62, compared to a current price of BDT288.90 — trading 8.5% below its estimated fair value. The current Accounts Payable is BDT50.5 Mil. Orion Infusions' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Accounts Payable is BDT50.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT288.90 is trading 8.5% below its estimated GF Value™ of BDT315.62. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • Accounts Payable: BDT50.5 Mil
  • GF Value™: BDT315.62 vs. price of BDT288.90 (8.5% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
80GF Score

Get the complete analysis for DHA:ORIONINFU

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT288.90
Price
BDT315.62
GF Value